CN117343927B - Nucleic acid extraction method of engineering cells - Google Patents
Nucleic acid extraction method of engineering cells Download PDFInfo
- Publication number
- CN117343927B CN117343927B CN202311656755.2A CN202311656755A CN117343927B CN 117343927 B CN117343927 B CN 117343927B CN 202311656755 A CN202311656755 A CN 202311656755A CN 117343927 B CN117343927 B CN 117343927B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- nuclease
- engineered
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 53
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 53
- 238000000605 extraction Methods 0.000 title abstract description 27
- 101710163270 Nuclease Proteins 0.000 claims abstract description 108
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000003834 intracellular effect Effects 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 215
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 17
- 108010034546 Serratia marcescens nuclease Proteins 0.000 claims description 13
- 238000010257 thawing Methods 0.000 claims description 10
- 239000002577 cryoprotective agent Substances 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 30
- 238000011282 treatment Methods 0.000 description 20
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 10
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000007710 freezing Methods 0.000 description 9
- 230000008014 freezing Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 108010053770 Deoxyribonucleases Proteins 0.000 description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 description 7
- 108010083644 Ribonucleases Proteins 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000007400 DNA extraction Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000002390 cell membrane structure Anatomy 0.000 description 2
- -1 concentration Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101150087690 ACTB gene Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure relates to methods for extracting intracellular nucleic acids, kits for intracellular nucleic acid extraction and the use of nucleases for the preparation of pretreatment reagents for intracellular nucleic acid extraction. The methods of the present disclosure include treating an engineered cell with a nuclease.
Description
Technical Field
The present disclosure relates to methods of extracting nucleic acids from engineered cells.
Background
Cell therapies have been used to treat diseases involving the introduction of exogenous nucleic acids into cells using genetically engineered methods and stringent cell detection procedures. However, the introduction of exogenous nucleic acid makes the cells more susceptible to contamination, thereby interfering with detection. How to remove the pollution while maintaining high detection efficiency is still a technical problem to be solved.
Disclosure of Invention
The present disclosure provides a method of extracting an engineered intracellular nucleic acid. The method comprises a pretreatment step prior to the nucleic acid extraction step. The pretreatment step can remove exogenous nucleic acid pollution and simultaneously maintain the efficiency of nucleic acid extraction.
In one aspect, a method of the present disclosure comprises: a) A pretreatment step comprising a contacting step of contacting the engineered cell with a nuclease; b) And extracting the nucleic acid in the cell. In one aspect, the present disclosure also provides a method of pretreatment of an engineered cell comprising a pretreatment step comprising a contacting step of contacting the engineered cell with a nuclease.
In one aspect, the nuclease is an endonuclease, an exonuclease, or a combination thereof, as previously described. In one aspect, the nuclease is a deoxyribonuclease, ribonuclease, or omnipotent nuclease. In one aspect, the nuclease is Benzonase or dnase i.
In one aspect, the method as described previously, wherein the contacting is for a time of no more than 2 hours. In one aspect, the contacting is for a period of 15 minutes to 60 minutes. In one aspect, the contacting is for about 30 minutes. In one aspect, the density of engineered cells upon contact is 1×10 4 personal/mL-1X 10 8 And each mL. In one aspect, the density of engineered cells upon contact is 5×10 5 personal/mL-1X 10 7 And each mL. In one aspect, the density of engineered cells upon contact is 5×10 5 personal/mL-7.5X10 6 And each mL. In one aspect, the concentration of nuclease at the time of the contacting is from 50 to 2000U/mL. In one aspect, the nuclease concentration upon contact is 75-1500U/mL. In one aspect, the nuclease concentration upon contact is 100-1000U/mL. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 4 Up to 2X 10 7 Individual cells. In one aspect, the nuclease to cell ratio at contact is 5X 10 per 1000U nuclease 5 Up to 1.5X10 7 Individual cells. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 6 From 7.5X10 6 Individual cells.
In one aspect, the method as described previously, wherein the pre-treatment step comprises the step of freeze-thawing the engineered cells prior to the contacting step. In one aspect, the temperature of the freeze-engineered cells does not exceed-20 ℃. In one aspect, the temperature of the freeze-engineered cells does not exceed-80 ℃.
In one aspect, a method as described previously comprises a) a pretreatment step comprising contacting an engineered cell with a nuclease for 15 minutes to 60 minutes at a density of 5 x 10 of the engineered cell 5 personal/mL-1X 10 7 The concentration of nuclease per m is 75-1500 U/mL; b) And extracting the nucleic acid in the cell. In one aspect, the pretreatment step comprises the steps of freezing-thawing the engineered cells, and contacting the thawed engineered cells with a totipotent nuclease for about 30 minutes at a density of 5X 10 of the engineered cells 5 personal/mL-7.5X10 6 The concentration of nuclease is 100-1000U/mL. In one aspect, the pretreatment step comprises the steps of freezing-thawing the engineered cells, and contacting the thawed cells with Benzonase for 30 minutes at a density of 1X 10 of the engineered cells 6 personal/mL-7.5X10 6 The concentration of nuclease was 1000U/mL.
In one aspect, a method as previously described comprises a) a pretreatment step comprising the steps of freeze-thawing the engineered cells, and a contacting step of contacting the engineered cells with a nuclease; b) And extracting the nucleic acid in the cell. In one aspect, the nuclease is Benzonase. In one aspect, the contacting is for a time of 30 minutes to 60 minutes. In one aspect, the time of contact is 30 minutes. In one aspect, the density of engineered cells upon contact is 5×10 5 personal/mL-1X 10 7 And each mL. In one aspect, the density of engineered cells upon contact is 1×10 6 personal/mL-7.5X10 6 And each mL. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 6 Up to 1X 10 7 And engineering the cells. In one aspect, the nuclease is Benzonase. In one aspect, the pretreatment step comprises the steps of freezing-thawing the engineered cells, and contacting the thawed cells with Benzonase for 30 minutes at a density of 1X 10 of the engineered cells 6 personal/mL-7.5X10 6 The nuclease to cell ratio was 1X 10 per 1000U nuclease per mL 6 Up to 1X 10 7 And engineering the cells.
In one aspect, the method as described previously, wherein the engineered cell is an engineered mammalian cell. In one aspect, the engineered cell is the engineered immune cell or engineered tumor cell. In one aspect, the engineered cell is an engineered T cell or an engineered NK cell. In one aspect, the engineered cell comprises an exogenous nucleic acid introduced via a viral vector, a non-viral vector, or a physical method. In one aspect, the exogenous gene is introduced into the engineered cell via lentiviral vectors, retroviral vectors, adenoviral vectors, adeno-associated viral vectors, cationic liposomes, polymeric nanoparticles, transposons, electroporation, or microinjection. In one aspect, the exogenous gene is introduced into the engineered cell via a lentiviral vector.
In another aspect, the present disclosure also provides a kit for extracting nucleic acid of an engineered cell comprising a pretreatment reagent comprising a nuclease and a nucleic acid extraction reagent. In one aspect, the nuclease is a deoxyribonuclease, ribonuclease, or omnipotent nuclease; in one aspect, the nuclease is Benzonase or dnase i.
In another aspect, the present disclosure also provides the use of a nuclease in the preparation of a pretreatment reagent for the extraction of nucleic acids in an engineered cell. In one aspect, the nuclease is a deoxyribonuclease, ribonuclease, or omnipotent nuclease; in one aspect, the nuclease is Benzonase or dnase i.
Drawings
FIG. 1 shows the effect of cell cryopreservation on nuclease pretreatment using agarose electrophoresis;
FIGS. 2A to 2D show the molecular weight distribution of DNA in lanes 1-4 of agarose electrophoresis, respectively.
Detailed Description
After reading this description it will become apparent to one skilled in the art how to implement the invention in various alternative embodiments and alternative applications. However, the embodiments herein are presented by way of example only and not limitation. As such, this detailed description should not be construed to limit the scope or breadth of the present invention as set forth below.
I. Terminology
"a" or "an" may mean one or more or one or more. "about" refers to a range in which its corresponding data value increases or decreases by up to 5%. It should be understood that "comprising," "including," and "containing" are intended to include any viable elements other than the elements so long as the addition of such elements does not render the solution containing such elements impractical. "consisting of … …" means having only the elements described by "… …". "comprising" encompasses the situation "consisting of … …".
The term "engineered cell" refers to a cell comprising an exogenous nucleic acid or genetic modification.
The term "pretreatment" refers to any pretreatment that increases the acid extraction efficiency within a cell, e.g., as used herein, the pretreatment brings a nuclease, surfactant, etc. into contact with the cell. Pretreatment does not or substantially not result in cell lysis.
The term "nuclease" refers to an enzyme capable of catalyzing the hydrolysis of bonds between nucleic acids within a DNA or RNA molecule.
The term "contacting" refers to the interaction, reaction, or physical contact of two or more substances. For example, in this context, contacting includes the process of mixing an engineered cell with a nuclease. The concentration or density of a substance during contact is that of the substance in the contact medium (e.g., a mixed liquor).
The term "immune cell" refers to a cell that is involved in an immune response intended to protect an organism from foreign substances, viruses and cells. Immune cells may be derived from a number of organs and tissues, such as thymus, spleen, lymph nodes, lymphoid tissue clusters (as in the gastrointestinal tract and bone marrow). Such cells include T cells, B cells, natural killer cells, macrophages, neutrophils, tumor-infiltrating lymphocytes, dendritic cells, mast cells, eosinophils and basophils, and progenitor cells that develop into these cells. In this context, immune cells are engineered (e.g., introduced with exogenous nucleic acid) into engineered cells prior to nucleic acid extraction.
II cell treatment method
The present disclosure provides methods of extracting intracellular nucleic acids comprising a pretreatment step and an extraction step. The present disclosure also provides a method of pretreatment of an engineered cell comprising a pretreatment step. In one aspect, the intracellular nucleic acid is intracellular DNA. In one aspect, the intracellular nucleic acid is genomic DNA of a cell. Surprisingly, the methods of the present disclosure are capable of greatly reducing contamination of intracellular nucleic acids with impurities and retaining higher recovery rates than intracellular nucleic acid extraction methods that do not include a pretreatment step.
2.1. Pretreatment step
In one aspect, the pretreatment step comprises a contacting step of contacting the engineered cell with a nuclease. In one aspect, the nuclease is an endonuclease, an exonuclease, or a combination thereof. In one aspect, the nuclease is a deoxyribonuclease, ribonuclease, or omnipotent nuclease. The omnipotent nuclease has DNase and RNase activities. In one aspect, the nuclease has no or substantially no activity to degrade proteins or disrupt cell membrane structures. In one aspect, the nuclease is Benzonase or dnase i. In one aspect, the nuclease is Benzonase.
In one aspect, wherein the time of contacting is no more than 6 hours, such as no more than 1,2, 3,4, 5, or 6 hours. In one aspect, wherein the contacting is for a time of 1 to 60 minutes, such as 1, 5, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes. In one aspect, the contacting is for a time of from 5 minutes to 60 minutes. In one aspect, the contacting is for a period of 15 minutes to 60 minutes. In one aspect, the contacting is for a time of 20 minutes to 40 minutes. In one aspect, the time of contact is about 30 minutes or 30 minutes. In one aspect, the contacting is performed at 25 to 42 ℃. In one aspect, the contacting is performed at 25, 37, or 42 ℃. In one aspect, the contacting is performed at about 37 ℃ or 37 ℃.
In one aspect, the density of engineered cells upon contact is 1×10 4 personal/mL-1X 10 8 And each mL. In one aspect, the density of engineered cells upon contact is 1×10 4 Per mL, 5X 10 4 Per mL, 1X 10 5 Per mL, 5X 10 5 Per mL, 1X 10 6 Per mL, 5X 10 6 personal/mL, 7.5X10 6 Per mL, 1X 10 7 Per mL, 5X 10 7 individual/mL or 1X 10 8 And each mL. In one aspect, the density of engineered cells upon contact is 5×10 4 From 1 to 10 per mL 7 And each mL. In one aspect, the density of engineered cells upon contact is 1×10 5 From 7.5X10 g/mL 6 And each mL. In one aspect, the density of engineered cells upon contact is 5×10 5 From 7.5X10 g/mL 6 And each mL. In one aspect, the density of engineered cells upon contact is about 5 x 10 5 Per mL, 1X 10 6 Per mL, 5X 10 6 individual/mL or 7.5X10 6 And each mL.
In one aspect, the concentration of nuclease at the time of the contacting is from 10 to 5000U/mL. In one aspect, the concentration of nuclease at the time of the contacting is from 50 to 2000U/mL. In one aspect, the concentration of nuclease at the time of the contacting is from 50 to 1500U/mL. In one aspect, the concentration of nuclease at the time of the contacting is from 100 to 1500U/mL. In one aspect, the nuclease concentration upon contact is 50U/mL, 75U/mL, 100U/mL, 200U/mL, 300U/mL, 400U/mL, 500U/mL, 600U/mL, 700U/mL, 800U/mL, 900U/mL, 1000U/mL, 1500U/mL, 2000U/mL, 3000U/mL, 4000U/mL, 5000U/mL. In one aspect, the nuclease concentration upon contact is 100-1000U/mL. In one aspect, the concentration of nuclease at the time of the contacting is about 100, 500 or 1000U/mL. In one aspect, the concentration of nuclease at the time of the contacting is about 1000U/mL.
In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 4 Up to 1X 10 8 And engineering the cells. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 4 Up to 2X 10 7 And engineering the cells. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 4 、5×10 4 Respectively, 1×10 5 Personal, 5×10 5 Respectively, 1×10 6 Personal, 5×10 6 Personal, 7.5X10) 6 Respectively, 1×10 7 2X 10 7 Personal, 5×10 7 Or 1X 10 8 And engineering the cells. In one aspect, the nuclease to cell ratio at contact is 5X 10 per 1000U nuclease 5 Up to 1.5X10 7 And engineering the cells. In one aspect, the nuclease to cell ratio at contact is 5X 10 per 1000U nuclease 5 Up to 1X 10 7 And engineering the cells. In one aspect, the nuclease to cell ratio at contact is 1X 10 per 1000U nuclease 6 From 7.5X10 6 And engineering the cells. In one aspect, the nuclease concentration at contact is 100U/mL and the cell density is 5X 10 5 And each. In one aspect, the nuclease concentration at contact is 500U/mL and the cell density is 5X 10 6 And each. In one aspect, the nuclease concentration at contact is 1000U/mL and the cell density is 1X 10 6 And each. In one aspect, the nuclease concentration at contact is 1000U/mL and the cell density is 7.5X10 6 And each. In one aspect, the nuclease concentration at contact is 1000U/mL and the cell density is 1X 10 7 And each.
In one aspect, the contacting is performed in a liquid medium. In one aspect, the contacting is performed in a liquid medium suitable for cell survival. In one aspect, the contacting is performed in a buffer suitable for cell survival. In one aspect, the contacting is performed in phosphate buffer. In one aspect, the contacting is performed in Du's Phosphate Buffer (DPBS). In one aspect, the buffer comprises 1 to 10mM Mg 2+ . In one aspect, the buffer comprises 1,2, 3,4, 5, 6, 7, 8, 9, or 10mM Mg 2+ . In one aspect, the buffer comprises 1,2, 3,4, 5, 6, 7, 8, 9, or 10mM Mg 2+ . In one aspect, the buffer comprises 1 to 5mM Mg 2+ . In one aspect, the buffer comprises 1 to 3mM Mg 2+ . In one aspect, the buffer comprises about 2mM or 2mM Mg 2+ 。
In one aspect, the method comprises the step of freeze-thawing the engineered cells prior to the contacting step. In one aspect, freezing is performed under suitable conditions to preserve the cells. In one aspect, the temperature of freezing is no more than-20 ℃, -30 ℃, -40 ℃, -50 ℃, -60 ℃, -70 ℃, -80 ℃, -90 ℃, or-100 ℃. In one aspect, the temperature of freezing is from-20 ℃ to-100 ℃. In one aspect, the temperature of freezing is from-60 ℃ to-80 ℃. In one aspect, the temperature of freezing is about-80 ℃ or-80 ℃. In one aspect, freezing is performed under liquid nitrogen conditions. In one aspect, the time of freezing is 1,2, 3, 6, 12, 24, 48, or 72 hours, or 5 days, 7 days, or 14 days. In one aspect, the time of freezing is from 6 hours to 7 days. In one aspect, the time of freezing is 24 hours to 3 days. In one aspect, thawing is performed at 0 ℃ to 37 ℃. In one aspect, thawing is performed at room temperature, about 25 ℃, or 25 ℃. In one aspect, the engineered cells are present in a cryoprotectant solution. In one aspect, the cryoprotectant solution may be formulated in any manner known in the art. In one aspect, the cryoprotectant solution is DMEM medium. In one aspect, the cryoprotectant solution comprises 0-20% DMSO, 0-40% serum, and 50-100% DMEM medium. In one aspect, the cryoprotectant solution comprises 5-10% DMSO, 10-20% serum, and 70-85% DMEM medium. In one aspect, the cryoprotectant solution comprises 10% DMSO, 20% fetal bovine serum, and 70% DMEM medium.
In one aspect, the pretreatment step further comprises a washing step after the contacting step. In one aspect, the washing step comprises washing the cells with a buffer centrifuge. In one aspect, the buffer is any buffer suitable in the art for cell washing. In one aspect, the buffer is PBS or DPBS. In one aspect, the volume of buffer used for a single wash is 0.5, 1,2, 3,4, 5, 6, 7, 8, 9, or 10 mL. In one aspect, the cells are washed 1,2, 3,4, 5, 6, 7, 8, 9, or 10 times. In one aspect, cells are washed 2 times with DPBS solution of 1 mL.
2.2. Extraction step
In one aspect, the extraction step may use a variety of techniques known to those skilled in the art. A first partExemplary extraction methods include (i) disrupting cell membranes (i.e., lysing cells), and (ii) extracting intracellular nucleic acids. Methods of lysing cells are well known to those skilled in the art, and for example, various mechanical shearing or ultrasonic techniques can be used to disrupt the cell membrane. The cell lysis step also includes the use of detergents and surfactants to solubilize lipids on the cell membrane and nuclear membrane. In one aspect, the cleaving step may further comprise using a protease to cleave a protein, and/or using an rnase to digest RNA in the sample. Methods of nucleic acid extraction are also well known, for example, using extraction with an organic solvent (e.g., a mixture of phenol and chloroform) followed by precipitation with ethanol. Other suitable methods also include salting out DNA extraction, trimethyl ammonium bromide salt DNA extraction, and guanidine thiocyanate DNA extraction. A variety of kits are commercially available for extracting DNA from biological samples, e.g., QIAamp from Qiagen (Germanown, MD) or Maxwell from Promega (Madison, wis.), among others ® And the reliaPrep ™ series of kits.
III kit
In one aspect, the present disclosure provides a kit for intracellular nucleic acid extraction comprising a pretreatment reagent and an intracellular nucleic acid extraction reagent. In another aspect, the present disclosure provides the use of a nuclease in the preparation of a pretreatment reagent for intracellular nucleic acid extraction. In one aspect, the nuclease is a deoxyribonuclease, ribonuclease, or omnipotent nuclease. The omnipotent nuclease has DNase and RNase activities. In one aspect, the nuclease has no or substantially no activity to degrade proteins or disrupt cell membrane structures.
In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 10 to 5000U/mL. In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 50 to 2000U/mL. In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 50 to 1500U/mL. In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 100 to 1500U/mL. In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 50U/mL, 75U/mL, 100U/mL, 200U/mL, 300U/mL, 400U/mL, 500U/mL, 600U/mL, 700U/mL, 800U/mL, 900U/mL, 1000U/mL, 1500U/mL, 2000U/mL, 3000U/mL, 4000U/mL, 5000U/mL. In one aspect, the nuclease is present in the pretreatment reagent at a concentration of 100-1000U/mL. In one aspect, the nuclease is at a concentration of about 100, 500 or 1000U/mL. In one aspect, the nuclease is at a concentration of about 1000U/mL.
In one aspect, the kit comprises an intracellular nucleic acid extraction reagent. Such nucleic acid extraction reagents are well known to those skilled in the art, for example, cell-cleavable detergents, cell membrane and nuclear membrane-soluble lipids, proteases, rnases, and organic solvents (e.g., mixtures of phenol and chloroform), salts, trimethylammonium bromide salts, guanidine thiocyanate, and the like for extracting nucleic acids. In one aspect, the kit comprises commercially available reagents, e.g., QIAamp from Qiagen, or Maxwell from Promega ® And the reliaPrep ™ series of reagents. In one aspect, the pretreatment kit intracellular nucleic acid extraction reagents are packaged in combination or separately. It is also within the scope of the present disclosure that the kit contains only pretreatment reagents and that the intracellular nucleic acid extraction reagents are described in the specification.
IV cells
In one aspect, the cells involved in the methods of the present disclosure are engineered to contain an exogenous gene. In one aspect, the cell is a mammalian cell. In one aspect, the cell is a human cell. In one aspect, the cell is an immune cell or an enriched immune cell. In one aspect, the cell is a tumor cell. In one aspect, the cell is a T cell or an enriched T cell. In one aspect, the cell is CD4 + T cells or enriched CD4 + T cells. In one aspect, the cell is CD8 + T cells or enriched CD8 + T cells. In one aspect, the cell is CD4 + T cells and CD8 + T cells. In one aspect, the cell is enriched for CD4 + T cells and enriched CD8 + T cells. In one aspect, the cells comprise engineered cells or an enriched population of engineered cells. In one aspect, theThe cells comprise genetically engineered T cells or an enriched population of genetically engineered T cells. In one aspect, the cell comprises a Chimeric Antigen Receptor (CAR) expressing T cell or an enriched CAR expressing T cell. In one aspect, the cells undergo a freeze-thaw step.
In one aspect, the method of making the engineered cells comprises cell isolation, selection, activation, transduction, incubation, expansion, washing, suspension, dilution, concentration, and/or formulation. In one aspect, the method comprises isolating cells, and preparing, processing, culturing the cells under stimulating conditions. In one aspect, the method comprises isolating cells from a biological sample, incubating the isolated cells with a viral vector to transduce exogenous nucleic acid into the cells. In one aspect, the method comprises isolating cells from a biological sample, incubating the isolated cells with a viral vector to transduce exogenous nucleic acid into the cells, and culturing the transduced cells. In one aspect, the isolating comprises the step of selecting cells. In one aspect, the transduction is performed after stimulation of the isolated cells with a stimulating agent.
In one aspect, the method of preparation includes one or more of the following: (a) Pre-washing a biological sample containing cells (e.g., a whole blood sample, a buffy coat sample, a Peripheral Blood Mononuclear Cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product); (b) Isolating (e.g., selecting) desired cells (e.g., CD 4) from the sample + And/or CD8 + T cells), for example by incubating the cells with an immunoaffinity reagent; (c) Introducing a vector encoding an exogenous nucleic acid (e.g., a recombinant receptor) into the isolated or selected cell, such as by incubating the isolated (e.g., selected) cell with a viral vector encoding the recombinant receptor; and (d) culturing or expanding the cells. In one aspect, the method may further comprise the step of activating the cells by exposing the cells to a stimulating condition, which may be performed before, during and/or after incubating the cells with the viral vector, e.g., atBetween step (b) and step (c). In one aspect, the viral vector is a lentiviral vector. In one aspect, a washing and/or suspending step may also be performed before or after any of the above steps. In one aspect, one, more or all of the steps of the cell culture method are performed under sterile conditions. In some embodiments of this method, cell isolation, transduction, washing, optional activation or stimulation, and formulation are all performed within a closed system.
In one aspect, the cell culture method comprises a step of genetic engineering. In one aspect, this step introduces exogenous nucleic acid into the cell. In one aspect, the genetic engineering step comprises introducing the recombinant protein into the cell via a vector. Such vectors include viral and non-viral systems. In one aspect, the viral system includes recombinant infectious viral particles, such as vectors of adenovirus, adeno-associated virus (AAV) and Human Immunodeficiency Virus (HIV), as well as recombinant lentiviral vectors or retroviral vectors (e.g., gamma retroviral vectors). In one aspect, the non-viral system includes a transposon system, such as a PiggyBac or a Sleeping Beauty gene transfer system. In one aspect, this step is performed by electroporation. In one aspect, the step is performed by transduction, transposon, electroporation, or a combination thereof. Other methods of introducing and expressing genetic material in immune cells include calcium phosphate transfection, protoplast fusion, cationic liposome-mediated transfection, tungsten particle-promoted microprojectile bombardment, and strontium phosphate DNA co-precipitation.
V. exogenous nucleic acid
In one aspect, the cells involved in the methods of the present disclosure comprise an exogenous nucleic acid encoding a recombinant protein. In one aspect, the recombinant protein is a chimeric receptor, a Chimeric Antigen Receptor (CAR), a T Cell Receptor (TCR), a chimeric antibody-T cell construct (caTCR), a Chimeric Signaling Receptor (CSR), or a combination thereof.
In one aspect, the recombinant protein is a Chimeric Antigen Receptor (CAR). In one aspect, the antigen is selectively expressed or over-expressed on cells of a disease or disorder (e.g., tumor or pathogenic cells) as compared to normal or non-targeted cells. In one aspect, the diseases and conditions include proliferative, neoplastic and malignant diseases and disorders, including cancers and tumors, including hematological cancers, cancers of the immune system, such as lymphomas, leukemias and/or myelomas, such as B-leukemia, T-leukemia and myelogenous leukemia, lymphomas and multiple myelomas. In one aspect, the CAR contains an extracellular antigen recognition domain that specifically binds to an antigen. Thus, the extracellular antigen-recognition domain that specifically binds an antigen includes one or more antigen-binding molecules, such as one or more antigen-binding fragments, domains, or portions, or one or more antibody variable domains, and/or antibodies. In one aspect, the antigen binding molecule is a full-length antibody, such as a single domain antibody, a monospecific antibody, or a multispecific antibody; or an antibody fragment, such as an scFv. In one aspect, the CAR comprises a spacer, which may be or comprise at least a portion of an immunoglobulin constant region or a variant or modified form thereof, such as a hinge region and/or CH1/CL and/or Fc region. In one aspect, the spacer is located between the extracellular antigen recognition domain and the transmembrane domain. In one aspect, the CAR comprises a transmembrane domain. In one aspect, the transmembrane domain is derived from a natural source or from a synthetic source. Where the source is natural, the transmembrane domain is derived from any membrane-bound protein or transmembrane protein. The transmembrane domain includes one or more of the α, β or ζ chains of T cell receptors, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In one aspect, the transmembrane domain is synthetic. In some aspects, the synthetic transmembrane domain comprises predominantly hydrophobic amino acid residues, such as leucine and valine. In one aspect, the CAR contains an intracellular signaling domain comprising a cytoplasmic signaling domain, e.g., an intracellular domain capable of inducing a primary activation signal in a T cell, e.g., the zeta chain of the CD3 zeta chain; and/or the intracellular signaling domain comprises an immune receptor tyrosine based activation motif (ITAM). In one aspect, the CAR contains a co-stimulatory domain. In one aspect, the co-stimulatory domain is the signaling region and/or transmembrane portion of CD28, 4-1BB, OX40, DAP10 or ICOS. In some aspects, the same CAR includes both the primary activation signaling region and the co-stimulatory component. In one aspect, the same CAR includes both a primary activation signaling domain and a co-stimulatory domain.
VI. Examples
After reading this description it will become apparent to one skilled in the art how to implement the invention in various alternative embodiments and alternative applications. However, the embodiments herein are presented by way of example only and not limitation. As such, this detailed description should not be construed to limit the scope or breadth of the present invention as set forth below.
In the examples below, unless otherwise indicated, the frozen stock solution contained 10% DMSO, 20% fetal bovine serum, and 70% DMEM medium. The DNA extraction process comprises the following steps: lysing the cells, and proteinase K treatment to remove proteins adsorbed on the DNA; adsorbing free DNA by using a silica gel column or magnetic beads; washing the DNA by using an ethanol solution to remove impurities; the DNA adsorbed on the silica gel column or the magnetic beads is eluted using a low-salt solution. The copy number of the gene is detected using techniques well known in the art or commercially available kits.
Example 1
This example describes the effect of different treatments on DNA extraction efficiency and cell detection. The cells of this example are engineered T cells. Prior to detection, exogenous nucleic acid is introduced into the cell using a lentiviral vector. The cells were then cultured at 1X 10 7 Up to 2X 10 7 The cell density of each/mL is dispersed in the frozen stock solution, and the frozen stock solution is placed at-80 ℃ or frozen in liquid nitrogen for at least 12 hours, thawed at room temperature and centrifugally collected. Preparation of a solution containing 100U/mL nuclease Benzonase and 2mM Mg 2+ The DPBS solution of (2) is used as a nuclease treatment solution. Cells were treated as described in groups 1-6 below.
DNA was extracted and DNA concentration was quantified using an ultraviolet spectrophotometer. The relative recovery rate of each treatment mode was calculated based on the DNA concentration of group 1. VSV-G (vesicular stomatitis virus glycoprotein G) can adsorb to the cell membrane surface during lentivirus transduction. The ACTB (human beta actin) gene is present in the cell genome. The effect of different treatment modes on detection of DNA in the nucleus and DNA adsorbed outside the cell is detected by taking 20 ng/mu L of DNA and adopting fluorescent quantitative PCR. The relative impurity removal rates for each treatment regime were calculated based on the VSV-G content of group 1. The results are shown in Table 2.
The results show that the surface adsorbed impurities can be removed more effectively by nuclease treatment than by conventional surfactant and buffer washes. Surprisingly, not only was the nuclease treatment for 30 minutes effective in removing impurities, but recovery was maintained comparable to the nuclease-untreated group. Furthermore, no change in Ct value of ACTB gene was caused by each treatment, indicating that genomic DNA of each group of cells was not degraded.
Example 2
This example evaluates the effect of different detection conditions on cell detection. The cells of this example are human T cells. Prior to detection, exogenous nucleic acid is introduced into the cell using a lentiviral vector. The cells were then cultured at 1X 10 7 Up to 2X 10 7 The cell density of each/mL is dispersed in the frozen stock solution, and the frozen stock solution is placed at-80 ℃ or frozen in liquid nitrogen for at least 12 hours, thawed at room temperature and centrifugally collected. According to Table 3, a solution containing 2mM Mg was used 2+ The DPBS solution of (1) was used as a blank treatment solution, and Benzonase was added to the blank treatment solution to obtain a nuclease-containing treatment solution (groups 2 to 5). Cells were added to 1mL of the treatment solution and incubated for 30 minutes. Cells were washed 2 times with 1mL DPBS solution and DNA was extracted. The results show that the treatment fluid is suitable for samples with different cell densities, and the plasmid residue clearance can be improved by reducing the cell density under the condition of the same cell number and enzyme proportion.
Example 3
This example evaluates the effect of cell cryopreservation on cell detection. The cells of this example are human T cells. Prior to detection, exogenous nucleic acid is introduced into the cell using a lentiviral vector. The transduced cells were split into two parts. A fraction of cells were grown in 1X 10 cells 5 ~1×10 7 Is dispersed in a culture medium solution and centrifuged. Another part of the cells was used as 1X 10 5 ~1×10 7 The cell density of each mL is dispersed in the frozen stock solution and is frozen at-80 ℃ for no less than 12 hours. Cryopreserved cells were thawed at room temperature and centrifuged. Preparation of a kit containing 1000U/mL nuclease and 2mM Mg 2+ The DPBS solution of (2) is used as a nuclease treatment solution. The unfrozen cells or frozen cell pellet were added to 1mL nuclease treatment solution and incubated at 37 ℃ for 30min. The cells were washed 2 times with 1mL DPBS solution and the DNA was extracted.
ALB (Albumin, human Albumin) was quantitatively detected by qPCR. The results are shown in Table 4. The frozen cells showed a stronger resistance to nucleases and their genomic DNA stability was higher than the non-frozen groups.
Example 4
This example evaluates the effect of cell cryopreservation on cell detection. The cell of this example is HT1080. Prior to detection, exogenous nucleic acid is introduced into the cell using a lentiviral vector. The transduced cells were split into two parts. A fraction of cells were grown in 1X 10 cells 5 ~1×10 7 Is dispersed in a culture medium solution and centrifuged. Another part of the cells was used as 1X 10 5 ~1×10 7 The cell density of each mL is dispersed in the frozen stock solution and is frozen at-80 ℃ for no less than 12 hours. Cryopreserved cells were thawed at room temperature and centrifuged. Preparation of a kit containing 1000U/mL nuclease and 2mM Mg 2+ The DPBS solution of (2) is used as a nuclease treatment solution. Adding unfrozen cells or frozen cell pellet into 1mL nuclease treatment solution, and adding into the solutionIncubate at 37 ℃ for 30min. The cells were washed 2 times with 1mL DPBS solution and the DNA was extracted. The extracted DNA was detected by agarose gel electrophoresis experiments. A0.8% agarose gel was prepared using a 1 XTEA solution. Gelred staining was added to the samples and markers. After the dyeing treatment, a DNA marker (molecular weight 250 b-10000 b) is spotted on the leftmost lane, 100ng of DNA which is not subjected to freeze-preservation extraction is added in lane 1, 200ng of DNA which is not subjected to freeze-preservation extraction is added in lane 2, 100ng of DNA which is subjected to freeze-preservation extraction is added in lane 3, and 200ng of DNA which is added in lane 4. Electrophoresis was performed at 140V for 30min. Agarose electrophoresis imaging was performed using a Gel Doc ™ EZ Gel imager.
As shown in FIG. 1, the agarose electrophoresis results show that the samples (lanes 1 and 2) which are not subjected to cell cryopreservation have three bands which are respectively more than 10kb, 500-1000bp and 200-500 bp; whereas samples subjected to cell cryopreservation (lanes 3, 4) showed only one band located over 10kb. Image processing was performed using gel imager software and the processing results for lanes 1-4 are shown in FIGS. 2A-2D, respectively. FIGS. 2A and 2B show that 80% of the DNA has a molecular weight greater than 10kb, and about 20% of the DNA is located in a small fragment region of <1000 bp; FIGS. 2C and 2D show that 100% of the DNA has a molecular weight of more than 10kb. The nuclease is adopted to treat the cells which are not frozen, which is easy to degrade the genome DNA and affects the detection result.
Claims (8)
1. A method of extracting an engineered intracellular nucleic acid comprising
a) A pretreatment step comprising the step of freezing-thawing said engineered cells, said frozen temperature not exceeding-80 ℃, said engineered cells being present in a cryoprotectant; and a contacting step of contacting the thawed engineered cells with a nuclease;
b) A step of extracting intracellular nucleic acid;
wherein the nuclease is Benzonase and the contacting is for 30 minutes to 60 minutes, and the ratio of nuclease to cell at the time of contacting is 5X 10 per 1000U of nuclease 5 Up to 1X 10 7 An engineered cell;
the engineered cell is an engineered mammalian cell.
2. The method of claim 1, wherein the time of contacting is 30 minutes.
3. The method of claim 1, wherein the density of engineered cells upon contact is 5 x 10 5 personal/mL-1X 10 7 And each mL.
4. The method of claim 3, wherein the engineered cells have a density of 1 x 10 at contact 6 personal/mL-7.5X10 6 And each mL.
5. The method of claim 1, wherein the nuclease to cell ratio at the time of contact is 1X 10 per 1000U of nuclease 6 Up to 1X 10 7 And engineering the cells.
6. A method of extracting an engineered intracellular nucleic acid comprising
a) A pretreatment step comprising the step of freezing-thawing the engineered cells, said frozen temperature not exceeding-80 ℃, said engineered cells being present in a cryoprotectant; and contacting the thawed cells with Benzonase for 30 minutes at a density of 1X 10 engineered cells 6 personal/mL-7.5X10 6 The nuclease to cell ratio was 1X 10 per 1000U nuclease per mL 6 Up to 1X 10 7 An engineered cell;
b) A step of extracting intracellular nucleic acid;
the engineered cell is an engineered mammalian cell.
7. The method of any one of claims 1 to 6, wherein the engineered cell is an engineered T cell.
8. The method of any one of claims 1 to 6, wherein the engineered cell comprises an exogenous nucleic acid introduced via a lentiviral vector.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311656755.2A CN117343927B (en) | 2023-12-06 | 2023-12-06 | Nucleic acid extraction method of engineering cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311656755.2A CN117343927B (en) | 2023-12-06 | 2023-12-06 | Nucleic acid extraction method of engineering cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117343927A CN117343927A (en) | 2024-01-05 |
CN117343927B true CN117343927B (en) | 2024-03-12 |
Family
ID=89371487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311656755.2A Active CN117343927B (en) | 2023-12-06 | 2023-12-06 | Nucleic acid extraction method of engineering cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117343927B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759700A (en) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | Target transgenic T cells of CD19 antigens and preparation method and application |
CN108384807A (en) * | 2018-02-26 | 2018-08-10 | 山东大学齐鲁医院 | A kind of preparation method of the stem cell of neural crest of viral genetic vector transfection |
WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
CN111684062A (en) * | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | Method for producing T cell |
CN113564271A (en) * | 2021-09-22 | 2021-10-29 | 首都医科大学附属北京佑安医院 | Primer probe set for pathogenic bacterium typing quantitative detection, kit and sample purification method |
CN114075609A (en) * | 2020-08-10 | 2022-02-22 | 北京荷塘生华医疗科技有限公司 | Method for determining infection titer of recombinant adenovirus |
CN114369640A (en) * | 2021-03-08 | 2022-04-19 | 南京诺唯赞生物科技股份有限公司 | Method for quickly and efficiently removing animal-derived host nucleic acid |
CN114410844A (en) * | 2022-01-29 | 2022-04-29 | 宁波熙宁检测技术有限公司 | Method for determining RCR negative and positive in CAR-T cell product by detecting GALV and ALB copy number through multiple qPCR (quantitative polymerase chain reaction) |
CN115003818A (en) * | 2020-01-22 | 2022-09-02 | 科济生物医药(上海)有限公司 | Method for transducing cells with viral vectors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019021595A2 (en) * | 2017-04-18 | 2020-05-12 | Glaxosmithkline Intellectual Property Development Limited | ADENO-ASSOCIATED VIRUS-PRODUCING CELL, NUCLEIC ACID VECTOR, METHODS FOR PRODUCING A STABLE PACKAGING OF ADEN-ASSOCIATED VIRUSES OF ADENO-ASSOCIATED VIRUS VIRUS WITH COME DEOCOULATED WITH DEFECTIVE DETICTION OF COME DEOCRATED WITH DEFEATURE ASSOCIATED, AND, ADENO-ASSOCIATED VIRUS PARTICLE WITH REPLICATION DEFECT. |
-
2023
- 2023-12-06 CN CN202311656755.2A patent/CN117343927B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759700A (en) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | Target transgenic T cells of CD19 antigens and preparation method and application |
WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
CN111684062A (en) * | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | Method for producing T cell |
CN108384807A (en) * | 2018-02-26 | 2018-08-10 | 山东大学齐鲁医院 | A kind of preparation method of the stem cell of neural crest of viral genetic vector transfection |
CN115003818A (en) * | 2020-01-22 | 2022-09-02 | 科济生物医药(上海)有限公司 | Method for transducing cells with viral vectors |
CN114075609A (en) * | 2020-08-10 | 2022-02-22 | 北京荷塘生华医疗科技有限公司 | Method for determining infection titer of recombinant adenovirus |
CN114369640A (en) * | 2021-03-08 | 2022-04-19 | 南京诺唯赞生物科技股份有限公司 | Method for quickly and efficiently removing animal-derived host nucleic acid |
CN113564271A (en) * | 2021-09-22 | 2021-10-29 | 首都医科大学附属北京佑安医院 | Primer probe set for pathogenic bacterium typing quantitative detection, kit and sample purification method |
CN114410844A (en) * | 2022-01-29 | 2022-04-29 | 宁波熙宁检测技术有限公司 | Method for determining RCR negative and positive in CAR-T cell product by detecting GALV and ALB copy number through multiple qPCR (quantitative polymerase chain reaction) |
Non-Patent Citations (3)
Title |
---|
三种DNA抽提方法对新鲜血细胞及冻血细胞DNA抽提效能的比较;金晶等;《第二军医大学学报》;第35卷(第1期);第101-105页 * |
不同保存时间对于血液DNA提取质量的影响;孙婷等;《中国继续医学教育》;第11卷(第3期);第47-49页 * |
影响外周血DNA提取质量因素分析;李江曼等;《河南大学学报(医学版)》;第33卷(第1期);第11-13页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117343927A (en) | 2024-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240002796A1 (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
EP3680329B1 (en) | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene | |
EP3394253B1 (en) | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene | |
US20210139935A1 (en) | Methods of manufacturing car-t cells | |
CN114929862A (en) | Production method for producing T cell expressing chimeric antigen receptor | |
EP4259160A1 (en) | Biallelic knockout of b2m | |
CN116802203A (en) | Cells expressing chimeric receptors from modified constant CD3 immunoglobulin superfamily chain loci, related polynucleotides and methods | |
CN117343927B (en) | Nucleic acid extraction method of engineering cells | |
EP3615674B1 (en) | Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene | |
CN109706182B (en) | Method for highly expressing CTLA4Ig in mesenchymal stem cells | |
WO2023205148A1 (en) | Chimeric antigen receptor compositions and uses | |
CN114149990A (en) | Method for editing BCL11A gene in hematopoietic stem/progenitor cells | |
EP4370676A2 (en) | Compositions and methods for targeting, editing or modifying human genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |